Genomics: Sequencing brain cancer

The research establishes the power of The Cancer Genome Atlas project and shows that it has the potential to expand rapidly our knowledge of the genetic alterations involved in cancers.


This press release is copyright Nature.

Editorial contacts: While the best contacts for stories will always be the authors themselves, in some cases the Nature editor who handled the paper will be available for comment if an author is unobtainable. Editors are contactable via Ruth Francis on +44 20 7843 4562. Feel free to get in touch with Nature's press contacts in London, New York, Washington and Tokyo (as listed at the end of this release) with any general editorial inquiry.

Warning: This document, and the Nature papers to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of Nature’s content may be guilty of insider trading under the US Securities Exchange Act of 1934.

The Nature journals press site is at

PICTURES: While we are happy for images from Nature to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).

HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at [email protected], citing the specific example.


Genomics: Sequencing brain cancer (AOP)
DOI: 10.1038/nature07385

One of the richest and most comprehensive analyses so far of cancer samples is reported online this week in Nature. The Cancer Genome Atlas pilot project describes nucleotide sequence, DNA copy number, gene expression and DNA methylation alterations in the brain cancer glioblastoma, currently in the public eye following the diagnosis of Senator Ted Kennedy with the disease.

The consortium has, for example, found roles for three genes — ERBB2, NF1 and TP53 — in glioblastoma, discovered novel mutations in the kinase regulatory subunit gene PIK3R1, and provides a global view of the signalling pathways altered in the development of the cancer.

The research establishes the power of The Cancer Genome Atlas project and shows that it has the potential to expand rapidly our knowledge of the genetic alterations involved in cancers.

Lynda Chin (Dana-Farber Cancer Institute, Boston, MA, USA)
Tel: +1 617 632 6091; E-mail: [email protected]

Please note, two related papers are being published by the journal Science. Registered reporters can log onto or contact AAAS at +1 202 326 6440, or [email protected].


For North America and Canada
Katherine Anderson, Nature London
Tel: +44 20 7843 4502; E-mail [email protected]

Katie McGoldrick, Nature Washington
Tel: +1 202 737 2355; E-mail: [email protected]

For Japan, Korea, China, Singapore and Taiwan
Mika Nakano, Nature Tokyo
Tel: +81 3 3267 8751; E-mail: [email protected]

For the UK/Europe/other countries not listed above
Rachel Twinn, Nature London
Tel: +44 20 7843 4658; E-mail [email protected]

About NPG

Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through Nature News. Scientific career information and free job postings are offered on Naturejobs.

NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Madrid, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to

Published: 04 Sep 2008

Contact details:

The Macmillan Building, 4 Crinan Street
N1 9XW
United Kingdom

+44 20 7833 4000
News topics: 
Content type: